vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $51.2M, roughly 1.7× Plymouth Industrial REIT, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -1.4%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 0.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.
IOVA vs PLYM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $51.2M |
| Net Profit | — | $-54.4M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | -102.5% |
| Net Margin | — | -106.3% |
| Revenue YoY | 17.7% | -1.4% |
| Net Profit YoY | — | -248.5% |
| EPS (diluted) | — | $-1.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | — | ||
| Q3 25 | $67.5M | $51.2M | ||
| Q2 25 | $60.0M | $47.2M | ||
| Q1 25 | $49.3M | $45.6M | ||
| Q4 24 | $73.7M | $47.6M | ||
| Q3 24 | $58.6M | $51.9M | ||
| Q2 24 | $31.1M | $48.7M | ||
| Q1 24 | $715.0K | $50.2M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $-54.4M | ||
| Q2 25 | $-111.7M | $-6.1M | ||
| Q1 25 | $-116.2M | $5.8M | ||
| Q4 24 | — | $147.4M | ||
| Q3 24 | $-83.5M | $-15.6M | ||
| Q2 24 | $-97.1M | $1.3M | ||
| Q1 24 | $-113.0M | $6.2M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | — | ||
| Q3 25 | -140.7% | -102.5% | ||
| Q2 25 | -189.8% | -10.3% | ||
| Q1 25 | -245.8% | — | ||
| Q4 24 | -117.5% | — | ||
| Q3 24 | -152.1% | -29.6% | ||
| Q2 24 | -327.6% | 2.7% | ||
| Q1 24 | -16464.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | -106.3% | ||
| Q2 25 | -186.2% | -12.9% | ||
| Q1 25 | -235.5% | 12.8% | ||
| Q4 24 | — | 309.9% | ||
| Q3 24 | -142.7% | -30.1% | ||
| Q2 24 | -312.2% | 2.7% | ||
| Q1 24 | -15800.8% | 12.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.23 | ||
| Q2 25 | $-0.33 | $-0.14 | ||
| Q1 25 | $-0.36 | $0.13 | ||
| Q4 24 | $-0.24 | $3.24 | ||
| Q3 24 | $-0.28 | $-0.35 | ||
| Q2 24 | $-0.34 | $0.03 | ||
| Q1 24 | $-0.42 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $470.1M |
| Total Assets | $913.2M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | — | ||
| Q3 25 | $300.8M | — | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | — | ||
| Q3 24 | $397.5M | — | ||
| Q2 24 | $412.5M | — | ||
| Q1 24 | $356.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $646.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $698.6M | — | ||
| Q3 25 | $702.3M | $470.1M | ||
| Q2 25 | $698.5M | $539.6M | ||
| Q1 25 | $767.9M | $571.0M | ||
| Q4 24 | $710.4M | $579.5M | ||
| Q3 24 | $773.5M | $436.5M | ||
| Q2 24 | $768.5M | $475.2M | ||
| Q1 24 | $680.0M | $484.6M |
| Q4 25 | $913.2M | — | ||
| Q3 25 | $904.9M | $1.6B | ||
| Q2 25 | $907.4M | $1.6B | ||
| Q1 25 | $966.7M | $1.4B | ||
| Q4 24 | $910.4M | $1.4B | ||
| Q3 24 | $991.1M | $1.5B | ||
| Q2 24 | $964.3M | $1.4B | ||
| Q1 24 | $869.8M | $1.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $20.0M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | — | ||
| Q3 25 | $-78.7M | $20.0M | ||
| Q2 25 | $-67.4M | $23.4M | ||
| Q1 25 | $-103.7M | $15.6M | ||
| Q4 24 | $-73.3M | $96.1M | ||
| Q3 24 | $-59.0M | $17.6M | ||
| Q2 24 | $-98.4M | $19.9M | ||
| Q1 24 | $-122.3M | $16.6M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 15.12× | ||
| Q1 24 | — | 2.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PLYM
Segment breakdown not available.
